Insuman Comb 25 Solostar (Insulin Human)

Insulin human mimics the action of naturally produced insulin by binding to insulin receptors on muscle, fat and liver cells. This triggers intracellular signaling that moves glucose transporters to the cell surface, increasing glucose uptake, while simultaneously suppressing hepatic glucose production, thereby lowering blood glucose concentrations.

The dose of Insuman Comb 25 Solostar is individualized. A qualified prescriber determines the starting amount and subsequent titration based on the patient’s blood glucose readings, carbohydrate intake, activity level, and overall clinical condition. Patients should follow the dosing instructions provided by their healthcare professional.

Insulin is generally considered the preferred glucose‑lowering therapy during pregnancy because it does not cross the placenta in harmful amounts. However, the decision to use Insuman Comb 25 Solostar should be made by a obstetrician‑endocrinology team who will weigh maternal benefits against any potential risks. Breastfeeding mothers should also consult their provider.

To request Insuman Comb 25 Solostar, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details—including cold‑chain handling if needed—and the necessary import documentation.

Insuman Comb 25 is a premixed human insulin containing 25 % protamine‑crystallized insulin and 75 % soluble insulin, offering both basal and rapid‑acting coverage in a single injection. Compared with basal‑only analogues, it reduces injection frequency but provides less flexibility for precise basal‑prandial adjustments than separate basal and rapid‑acting insulin analogues.

The product must be stored in a refrigerator at 2 °C to 8 °C. Keep it in the original carton to protect from light, do not freeze or shake the vial or pen. Once in use, it may be kept at controlled room temperature (up to 30 °C) for a maximum of 28 days, after which any remaining insulin should be discarded.

Insuman Comb 25 Solostar is administered by subcutaneous injection, typically into the abdomen, thigh, or upper arm. The injection site should be rotated with each dose to minimize lipodystrophy. Patients should be trained by a healthcare professional on proper injection technique, dose measurement, and disposal of used sharps.

The most serious risks include severe hypoglycemia, which can cause loss of consciousness or seizures, and rare allergic reactions such as anaphylaxis. Patients should be educated to recognize early signs of hypoglycemia, carry rapid‑acting glucose sources, and seek immediate medical attention if an allergic reaction occurs.

Insuman Comb 25 should be avoided in individuals with a known hypersensitivity to human insulin or any of the product’s excipients. It is also contraindicated in patients experiencing hypoglycemia at the time of administration. Clinicians should assess each patient’s medical history before prescribing.